Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Total Non-Current Liabilities (2017 - 2025)

Historic Total Non-Current Liabilities for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to $396.0 million.

  • Autolus Therapeutics' Total Non-Current Liabilities rose 1312.42% to $396.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $396.0 million, marking a year-over-year increase of 1312.42%. This contributed to the annual value of $355.0 million for FY2024, which is 3468.94% up from last year.
  • Latest data reveals that Autolus Therapeutics reported Total Non-Current Liabilities of $396.0 million as of Q3 2025, which was up 1312.42% from $374.0 million recorded in Q2 2025.
  • Over the past 5 years, Autolus Therapeutics' Total Non-Current Liabilities peaked at $396.0 million during Q3 2025, and registered a low of $92.1 million during Q4 2021.
  • For the 5-year period, Autolus Therapeutics' Total Non-Current Liabilities averaged around $248.5 million, with its median value being $244.4 million (2023).
  • Per our database at Business Quant, Autolus Therapeutics' Total Non-Current Liabilities soared by 939.02% in 2021 and then surged by 12300.58% in 2023.
  • Autolus Therapeutics' Total Non-Current Liabilities (Quarter) stood at $92.1 million in 2021, then surged by 107.88% to $191.5 million in 2022, then soared by 37.64% to $263.6 million in 2023, then skyrocketed by 34.69% to $355.0 million in 2024, then grew by 11.56% to $396.0 million in 2025.
  • Its last three reported values are $396.0 million in Q3 2025, $374.0 million for Q2 2025, and $374.8 million during Q1 2025.